Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio
Eli Lilly is adding three new preclinical candidates to its immune and inflammatory medicines armory through TRexBio, a Bay Area biotech that specializes in T regulatory cells, or Tregs.
In exchange for global licenses on the candidates — TRB-051, TRB-031, and TRB-041 — TRexBio will get $55 million upfront. All in all, TRexBio could get over $1.1 billion when factoring in downstream milestones. According to TRexBio’s website, TRB-051 is the furthest along, in the IND-enabling phase.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.